Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (noted as Scisparc Ltd. in metadata) covers the month of January 2020. The report details the outcomes of the Annual and Special General Meeting of Shareholders held on January 15, 2020.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and shareholder meeting results rather than financial performance.
Material Changes and Corporate Actions
- Shareholder Approval: Shareholders approved all agenda items as originally proposed, with specific exceptions noted below.
- Director Resignations: Dr. Yafit Stark and Mr. Zohar Heiblum resigned from the Board of Directors on December 31, 2019. Consequently, all resolutions relating to these former directors were not raised at the meeting and are considered null and void.
- Executive Compensation Error: A resolution to grant options to purchase 1,300,000 Ordinary Shares (equivalent to 32,500 American Depositary Shares) to director Eric So was accidentally omitted from the proxy voting card due to a technical error.
Outlook, Risks, and Management Commentary
Management plans to reconvene a special general meeting of shareholders in the near future to vote on the omitted option grant for Eric So. The filing incorporates this report by reference into registration statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the date and agenda of the upcoming special general meeting to approve the Eric So option grant.
- Confirm the current composition of the Board of Directors following the resignations of Dr. Stark and Mr. Heiblum.
- Review the specific terms of the 1,300,000 share option grant intended for Eric So.